Key Insights

Highlights

Success Rate

71% trial completion

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

7.7%

2 terminated out of 26 trials

Success Rate

71.4%

-15.1% vs benchmark

Late-Stage Pipeline

19%

5 trials in Phase 3/4

Results Transparency

120%

6 of 5 completed with results

Key Signals

6 with results71% success

Data Visualizations

Phase Distribution

15Total
Not Applicable (3)
P 1 (2)
P 2 (5)
P 3 (5)

Trial Status

Recruiting8
Unknown5
Completed5
Withdrawn4
Not Yet Recruiting2
Terminated2

Trial Success Rate

71.4%

Benchmark: 86.6%

Based on 5 completed trials

Clinical Trials (26)

Showing 20 of 20 trials
NCT07705789Not ApplicableNot Yet RecruitingPrimary

The Role of interferOn and Complement in SecondAry thRombotic micrioangiOpathy

NCT04098445Recruiting

TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients

NCT05702996Phase 3WithdrawnPrimary

Study Evaluating the Efficacy of Eculizumab in the Treatment of Gemcitabine-induced Thrombotic Microangiopathies

NCT07459114Phase 1Not Yet RecruitingPrimary

TGD001 Treatment in Thrombotic Microangiopathies

NCT06291025Not ApplicableRecruitingPrimary

Efficacy and Safety of Immunosuppression, Caplacizumab and Plasma Infusion Without Therapeutic Plasma Exchange in Immune-mediated Thrombotic Thrombocytopenic Purpura

NCT03205995Phase 3TerminatedPrimary

Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome

NCT07205861Recruiting

Retrospective Epidemiological Study of Patients in the National Cohort of the French TMA Center

NCT04745195RecruitingPrimary

Complement Prospective Evaluation of Thrombotic Microangiopathy on Endothelium

NCT06291415Phase 1Withdrawn

The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)

NCT06102694RecruitingPrimary

Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic Microangiopathy

NCT04784455Phase 3TerminatedPrimary

Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy

NCT05855083Phase 2RecruitingPrimary

Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA

NCT06727669Recruiting

Longitudinal Cohort of Thrombosis and Hemostasis Diseases

NCT02222545Phase 2CompletedPrimary

Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies

NCT06182410Phase 2Withdrawn

Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma

NCT06098378UnknownPrimary

Study of Patients With Thrombotic Microangiopathy Associated With Mitomycin C, Treated or Not With Eculizumab

NCT03518203Phase 2CompletedPrimary

Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients

NCT05996679UnknownPrimary

Automated Surveillance, Alert, and Rapid Diagnosis of Thrombotic Microangiopathies: the ASARD-TMA Study

NCT04570397Phase 3Unknown

Ravulizumab and COVID-19

NCT05634928RecruitingPrimary

Construction of a Database for TMA

Scroll to load more

Research Network

Activity Timeline